MX2017011732A - Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos. - Google Patents

Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.

Info

Publication number
MX2017011732A
MX2017011732A MX2017011732A MX2017011732A MX2017011732A MX 2017011732 A MX2017011732 A MX 2017011732A MX 2017011732 A MX2017011732 A MX 2017011732A MX 2017011732 A MX2017011732 A MX 2017011732A MX 2017011732 A MX2017011732 A MX 2017011732A
Authority
MX
Mexico
Prior art keywords
fusion proteins
surface glycoproteins
virus surface
modified alpha
alpha virus
Prior art date
Application number
MX2017011732A
Other languages
English (en)
Inventor
Babad Jeffrey
Martina Pola Elin
Leonardi Peter
Original Assignee
Omnicyte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omnicyte filed Critical Omnicyte
Publication of MX2017011732A publication Critical patent/MX2017011732A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a proteínas de fusión que comprenden una o más glicoproteínas de la superficie del virus alfa modificado y uno o más antígenos específicos del tumor. También se describen proteínas de fusión que comprenden una o más glicoproteínas de la superficie del virus alfa modificado y uno o más antígenos virales específicos. También se describen proteínas de fusión que comprenden una o más glicoproteínas de la superficie del virus alfa modificado. También se refiere a métodos para activar el sistema inmune en pacientes con cáncer para infiltrar y eliminar células tumorales o células infectadas con un virus latente. La presente descripción proporciona una tecnología de plataforma que estimula una respuesta inmune más rápida, más amplia y más fuerte usando las proteínas de fusión.
MX2017011732A 2015-03-18 2016-03-18 Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos. MX2017011732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134933P 2015-03-18 2015-03-18
PCT/US2016/023203 WO2016149643A2 (en) 2015-03-18 2016-03-18 Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof

Publications (1)

Publication Number Publication Date
MX2017011732A true MX2017011732A (es) 2018-08-15

Family

ID=56919485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011732A MX2017011732A (es) 2015-03-18 2016-03-18 Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.

Country Status (12)

Country Link
US (3) US10660948B2 (es)
EP (1) EP3270958A4 (es)
JP (1) JP6921053B2 (es)
KR (1) KR20170121301A (es)
CN (2) CN114262380A (es)
AU (2) AU2016232771B2 (es)
BR (1) BR112017019776B1 (es)
CA (1) CA2979697A1 (es)
HK (1) HK1248610A1 (es)
MX (1) MX2017011732A (es)
RU (1) RU2017132190A (es)
WO (1) WO2016149643A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3270958A4 (en) * 2015-03-18 2018-11-14 Omnicyte Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof
WO2018161092A1 (en) * 2017-03-03 2018-09-07 New York University Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
CN110856724B (zh) * 2018-08-24 2022-05-27 杭州康万达医药科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用
JP7457037B2 (ja) * 2019-05-31 2024-03-27 広州威溶特医薬科技有限公司 Ｍ１ウイルス変異体及びその使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) * 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
AU8762991A (en) * 1990-09-26 1992-04-15 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
CA2298840A1 (en) * 1997-08-05 1999-02-18 Stressgen Biotechnologies Corporation Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
US6168932B1 (en) * 1998-07-13 2001-01-02 Parker Hughes Institute Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US20050130259A1 (en) * 2002-06-25 2005-06-16 Akira Ideno Expression vector, host, fused protein, process for producing fused protein and process for producing protein
MXPA05002455A (es) 2002-09-06 2005-06-03 Mannkind Corp Secuencias de epitopes.
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
CN100528230C (zh) * 2003-02-19 2009-08-19 台桂香 重组人muc1-mbp融合蛋白抗肿瘤疫苗及生产工艺
CA2558811A1 (en) * 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
CN100342017C (zh) * 2004-05-10 2007-10-10 中国医学科学院肿瘤医院肿瘤研究所 基因重组趋化抗原疫苗
WO2007046839A2 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
ES2373055T3 (es) 2005-08-09 2012-01-31 Oncotherapy Science, Inc. Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
JP5137168B2 (ja) 2006-02-27 2013-02-06 独立行政法人科学技術振興機構 安定同位体標識脂肪族アミノ酸、その標的蛋白質への組み込み方法並びに蛋白質のｎｍｒ構造解析方法
DK2456786T4 (en) * 2009-07-24 2017-08-07 Immune Design Corp LENTIVIRUS VECTORS DETERMINED PSEUDOTYPE WITH A COAT PEGYCLOPROTEIN FROM SINDBIS VIRUS
KR20120052352A (ko) 2009-08-07 2012-05-23 트랜스진 에스.에이. Ｈｂｖ 감염을 치료하는 조성물
EP2675473A1 (en) * 2011-02-15 2013-12-25 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
EP3632463A1 (en) * 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US9637532B2 (en) * 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
EP3270958A4 (en) * 2015-03-18 2018-11-14 Omnicyte Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof

Also Published As

Publication number Publication date
CA2979697A1 (en) 2016-09-22
US20180243389A1 (en) 2018-08-30
EP3270958A2 (en) 2018-01-24
US20230181706A1 (en) 2023-06-15
JP2018509937A (ja) 2018-04-12
BR112017019776B1 (pt) 2020-07-28
AU2016232771B2 (en) 2021-08-19
WO2016149643A2 (en) 2016-09-22
KR20170121301A (ko) 2017-11-01
US11471518B2 (en) 2022-10-18
JP6921053B2 (ja) 2021-08-18
CN114262380A (zh) 2022-04-01
RU2017132190A (ru) 2019-04-18
BR112017019776A2 (pt) 2018-05-22
HK1248610A1 (zh) 2018-10-19
AU2016232771A1 (en) 2017-10-05
EP3270958A4 (en) 2018-11-14
CN107530410A (zh) 2018-01-02
CN107530410B (zh) 2021-11-09
US10660948B2 (en) 2020-05-26
RU2017132190A3 (es) 2019-08-30
AU2021269306A1 (en) 2021-12-09
US20210077600A1 (en) 2021-03-18
WO2016149643A3 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
MX2022000012A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
MX2022006006A (es) Proteinas de fusion inmunomoduladoras y usos de las mismas.
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
MX2021014448A (es) Modulacion de celulas mieloides estimulantes y no estimulantes.
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
MX2017000838A (es) Cepa de listeria recombinante que expresa proteinas de fusion con antigenos heterologos y metodos para el uso de estas.
EP3258967A4 (en) Bivalent antibody directed against nkg2d and tumor associated antigens
EP4321171A3 (en) Sirp alpha-antibody fusion proteins
MX2018004503A (es) Receptores de antigeno quimerico anti-cd30.
SG10201903349YA (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
MX2017011732A (es) Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.
EA201891124A3 (ru) Новые мукозные адъюванты и системы доставки
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
AU2015255979B2 (en) Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
MX2017011991A (es) Terapia virica con una combinacion de anticuerpos.
MX2021001883A (es) Virus recombinantes del mixoma y usos de los mismos.
WO2016116905A9 (en) Cmv antigens and uses thereof
WO2016077789A8 (en) Neutralizing antibodies to ebola virus glycoprotein and their use
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
MX2016014868A (es) Metodos para secar por congelacion y rehidratar productos biologicos.
SG11202008589TA (en) Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy
MX2018013685A (es) Terapia de combinacion de cebadadura:refuerzo.